U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 22

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated August 4, 2016.	4. Expiration Date: January 31, 2021
1. Fayette Memorial Hospital d/b/a Fayette Regional Health System 2. 1941 Virginia Avenue Connersville, IN 47331	3. License number: 13-16518-01 is amended in its entirety to read as follows:	5. Docket No.: 030-11441 Reference No.:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. 5 millicuries total	D. In vitro studies.

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at: 1941 Virginia Avenue, Connersville, Indiana, 47331.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 13-16518-01	Docket or Reference Number 030-11441
	Amendment No. 22	

11. The Radiation Safety Officer (RSO) for this license is Patrick Byrne, DABR, CHP, DABSNM.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)	Material and Use
Margaret Brengle, M.D.	10 CFR 35.100, 35.200, and 31.11.
Charles A. Lerner, M.D.	10 CFR 35.100, 35.200, and 31.11.
John Marvel, M.D.	10 CFR 35.300.
Frank J. Pistoia, M.D.	10 CFR 35.100, 35.200, and 31.11.
Caryn Cockerill Anderson, M.D.	10 CFR 35.100, 35.200, and 31.11.
Laura Dugan, M.D.	10 CFR 35.100, 35.200, and 31.11.
James Currier, M.D.	10 CFR 35.300.
Michael S. Conley, M.D.	10 CFR 35.100, 35.200, and 31.11.
Thomas Hagman, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
John Mark Michael, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Theodore P. Labus, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Christina N. Shinaver, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Richard L. Hallet, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Jonathan Kahn, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
David R. Gulliver, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 13-16518-01	Docket or Reference Number 030-11441
	Amendment No. 22	

Authorized User(M.D.,D.O.,etc.)	Material and Use
Eric E. Beltz, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide 1-131 in quantities less than or equal to 33 millicuries), and 31.11.
Charles C. Mulry, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide 1-131 in quantities less than or equal to 33 millicuries), and 31.11.
J. Michael Phelps, Jr., M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide 1-131 in quantities less than or equal to 33 millicuries), and 31.11.
Timothy L. Davis, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide 1-131 in quantities less than or equal to 33 millicuries), and 31.11.
Warren Kent Hansen, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide 1-131 in quantities less than or equal to 33 millicuries), and 31.11.
Carlo Roberto Lazzaro, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide 1-131 in quantities less than or equal to 33 millicuries), and 31.11.
Patricia Ellen Ladd, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide 1-131 in quantities less than or equal to 33 millicuries), and 31.11.
Marc P. Underhill, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide 1-131 in quantities less than or equal to 33 millicuries), and 31.11.
Vincent L. Flanders, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide 1-131 in quantities less than or equal to 33 millicuries), and 31.11.
Ryan N. Sauer, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide 1-131), and 31.11.
Larry L. Stover, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide 1-131), and 31.11.
Kelly K. Horst, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide 1-131), and 31.11.
Eric D. Elliott, M.D.	10 CFR 35.100, 35.200, and 31.11.
Steven A. Fritsch, M.D.	10 CFR 35.100, 35.200, and 31.11.
Jane S. Mitchell, M.D.	10 CFR 35.100, 35.200, and 31.11.
Jack J. Moss, M.D.	10 CFR 35.100, 35.200, and 31.11.
Jeffrey I. Reider, M.D.	10 CFR 35.100, 35.200, and 31.11.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number: 13-16518-01
Amendment No. 22
Docket or Reference Number: 030-11441

Authorized User(M.D.,D.O.,etc.)	Material and Use
Lori J. Wells, M.D.	10 CFR 35.100, 35.200, and 31.11.
Janalyn P. Ferguson, M.D.	10 CFR 35.100, 35.200, and 31.11.
Edward R. Bartley, M.D.	10 CFR 35.100, 35.200, and 31.11.
Peter D. Arfken, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Brian J. Wiegel, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
John A. Morton, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Homer F. Beltz, M.D.	10 CFR 35.100, 35.200, and 31.11.
Martha Dwenger, M.D.	10 CFR 35.100, 35.200, and 35.300.
Andrew J. Sundblad, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide 1-131).
Stewart S. Worrell, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide 1-131 in quantities less than or equal to 33 millicuries).
Parin Bhayani, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide 1-131).
Matthew M. Jones, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide 1-131).
Matthew Locker, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide 1-131).
Shrey K. Thawait, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131).
Joshua D. Dowell, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide 1-131).
Michael S. Skulski, M.D.	10 CFR 35.100, 35.200, and 31.11.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 13-16518-01	Docket or Reference Number 030-11441
	Amendment No. 22	

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated October 12, 2010 (ML103010114)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: November 15, 2016

By: _____

Cassandra F. Frazier
Region III